Trials / Completed
CompletedNCT02878603
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic thrombocytopenic purpura (aTTP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Caplacizumab | |
| OTHER | Standard of Care | • PE with plasma (e.g., fresh frozen plasma, solvent detergent/viral-inactivated plasma, cryosupernatant), • Corticosteroid treatment and • Use of other immunosuppressive agents (e.g., rituximab). |
Timeline
- Start date
- 2016-10-06
- Primary completion
- 2020-10-23
- Completion
- 2020-10-23
- First posted
- 2016-08-25
- Last updated
- 2022-03-28
- Results posted
- 2021-11-22
Locations
45 sites across 13 countries: United States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel, Italy, Spain, Switzerland, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT02878603. Inclusion in this directory is not an endorsement.